Celgene (BUE:CELG) Total Liabilities: ARS1,637,289.55 Mil (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Celgene Total Liabilities?

Celgene BUE:CELG 10 Total Liabilities is ARS1,637,289.55 Mil as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Celgene's Total Liabilities for the quarter that ended in Sep. 2019 was ARS1,637,289.55 Mil.

Celgene's quarterly Total Liabilities increased from Mar. 2019 (ARS1,152,138.66 Mil) to Jun. 2019 (ARS1,301,588.66 Mil) and increased from Jun. 2019 (ARS1,301,588.66 Mil) to Sep. 2019 (ARS1,637,289.55 Mil).

Celgene's annual Total Liabilities increased from Dec. 2016 (ARS340,606.82 Mil) to Dec. 2017 (ARS443,385.88 Mil) and increased from Dec. 2017 (ARS443,385.88 Mil) to Dec. 2018 (ARS1,105,472.95 Mil).

Celgene Total Liabilities Historical Data

* Premium members only.

The historical data trend for Celgene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Total Liabilities Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92,481.63 272,390.61 340,606.82 443,385.88 1,105,472.95

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,080,234.64 1,105,472.95 1,152,138.66 1,301,588.66 1,637,289.55

Celgene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celgene's Total Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=152969.193+(745390.184+91396.924
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+106554.336+9162.315+0)
=1,105,472.95

Total Liabilities=Total Assets (A: Dec. 2018 )-Total Equity (A: Dec. 2018 )
=1337773.469-232300.517
=1,105,472.95

Celgene's Total Liabilities for the quarter that ended in Sep. 2019 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=280133.33+(1022830.598+173818.005
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+160507.617+0+0)
=1,637,289.55

Total Liabilities=Total Assets (Q: Sep. 2019 )-Total Equity (Q: Sep. 2019 )
=2313267.102-675977.551
=1,637,289.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ARS1,637,289.55 Mil mean?
Celgene (BUE:CELG) has a Total Liabilities of ARS1,637,289.55 Mil as of Sep. 2019. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celgene and its competitors.
Is Celgene's Total Liabilities too high?
Celgene's current Total Liabilities is ARS1,637,289.55 Mil. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Total Liabilities compare to GILD and BIIB?
Celgene's Total Liabilities of ARS1,637,289.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celgene and its competitors. Celgene's current Total Liabilities is ARS1,637,289.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Total Liabilities of ARS1,637,289.55 Mil. The current Total Liabilities is ARS1,637,289.55 Mil. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Total Liabilities is ARS1,637,289.55 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.